PDE4A and COVID-19: The anti-inflammatory activities of rolipram have been consistently proven.52 In a pneumococcal pneumonia model, rolipram downregulated airway cytokine expression levels, and ameliorated neutrophil recruitment and lung damage.53 Our results, therefore, provide the basis for repurposing PDE4 inhibitors such as rolipram or roflumilast as the adjunct therapy for COVID-19 as described previously.54